Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Common Equity (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Common Equity for 10 consecutive years, with -$189.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 67.79% to -$189.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$189.5 million through Dec 2025, down 67.79% year-over-year, with the annual reading at -$189.5 million for FY2025, 67.79% down from the prior year.
  • Common Equity hit -$189.5 million in Q4 2025 for Ascendis Pharma A, down from -$113.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.0 billion in Q4 2021 to a low of -$189.5 million in Q4 2025.
  • Historically, Common Equity has averaged $164.1 million across 5 years, with a median of -$113.0 million in 2024.
  • Biggest five-year swings in Common Equity: crashed 158.34% in 2023 and later grew 27.94% in 2024.
  • Year by year, Common Equity stood at $1.0 billion in 2021, then crashed by 73.42% to $268.7 million in 2022, then plummeted by 158.34% to -$156.8 million in 2023, then increased by 27.94% to -$113.0 million in 2024, then crashed by 67.79% to -$189.5 million in 2025.
  • Business Quant data shows Common Equity for ASND at -$189.5 million in Q4 2025, -$113.0 million in Q4 2024, and -$156.8 million in Q4 2023.